IRIS
PEVIANI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 790
EU - Europa 533
AS - Asia 306
SA - Sud America 1
Totale 1.630
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 783
CN - Cina 262
IE - Irlanda 189
IT - Italia 106
FI - Finlandia 65
UA - Ucraina 61
DE - Germania 47
SG - Singapore 30
SE - Svezia 23
BE - Belgio 17
GB - Regno Unito 13
CA - Canada 7
FR - Francia 6
IN - India 5
VN - Vietnam 3
JP - Giappone 2
MY - Malesia 2
NL - Olanda 2
RU - Federazione Russa 2
BR - Brasile 1
CZ - Repubblica Ceca 1
GR - Grecia 1
IR - Iran 1
KR - Corea 1
Totale 1.630
Salva come PNG Salva come JPEG
Città #
Dublin 189
Chandler 175
Jacksonville 80
Nanjing 77
Ann Arbor 54
Pavia 52
Boardman 51
Ashburn 48
Beijing 38
Princeton 35
Lawrence 34
Wilmington 31
Nanchang 29
Helsinki 28
Medford 23
Singapore 20
Piscataway 19
Hebei 18
New York 18
Shanghai 18
Jiaxing 15
Changsha 14
Brussels 13
Shenyang 12
Tianjin 12
Woodbridge 9
Chicago 8
Milan 8
Seattle 8
Falls Church 6
Los Angeles 6
Toronto 6
Washington 6
Hangzhou 5
Munich 5
Des Moines 4
Piemonte 4
Pune 4
Tappahannock 4
Fairfield 3
Auburn Hills 2
Calusco d'Adda 2
Casorate Primo 2
Dallas 2
Dong Ket 2
Jinan 2
Ningbo 2
Norwalk 2
Reggio Emilia 2
Rockville 2
Torino 2
Turin 2
Amsterdam 1
Augsburg 1
Borås 1
Brno 1
Changteh 1
Clifton 1
Gallarate 1
Hanoi 1
Houston 1
Jinhua 1
Kunming 1
Lanzhou 1
Moscow 1
Nanyang 1
Newark 1
Nuremberg 1
Padova 1
Prineville 1
Qingdao 1
Redwood City 1
Santa Clara 1
Shaoxing 1
Suizenji 1
São Paulo 1
Tokyo 1
Verona 1
West Palm Beach 1
Zhengzhou 1
Totale 1.241
Salva come PNG Salva come JPEG
Nome #
Studies on the Enantiomers of RC-33 as Neuroprotective Agents: Isolation, Configurational Assignment, and Preliminary Biological Profile 89
(R)-RC-33 as Promising Neuroprotective Agent Acting as Sigma1 Receptor Agonist 83
Identification of RC-33 as a potent and selective sigma1 receptor agonist potentiating NGF-induced neurite outgrowth in PC12 cells. Part 2: g-scale synthesis, physicochemical characterization and in vitro metabolic stability. 76
Chemical, pharmacological, and in vitro metabolic stability studies on enantiomerically pure RC-33 compounds, promising neuroprotective agents acting as sigma1 receptor agonists. 75
A step forward in the sigma enigma: a role for chirality in the sigma1 receptor- ligand interaction? 74
In Situ Agar – Carbomer Hydrogel Polycondensation:a Chemical Approach to Regenerative Medicine 72
Inter- and intracellular signaling in amyotrophic lateral sclerosis: role of p38 mitogen-activated protein kinase. 69
Identification of a potent and selective sigma1 receptor agonist potentiating NGF-induced neurite outgrowth in PC12 cells. 66
Accumulation of human SOD1 and ubiquitinated deposits in the spinal cord of SOD1G93A mice during motor neuron disease progression correlates with a decrease of proteasome. 62
Development of easy-to-use reverse-phase liquid chromatographic methods for determining PRE-084, RC-33 and RC-34 in biological matrices. The first step for in vivo analysis of sigma1 receptor agonists. 57
Use of arylalkanolamines as sigma-1 receptor antagonists 54
Neuroprotective effects of the Sigma-1 receptor (S1R) agonist PRE-084,in a mouse model of motor neuron disease not linked to SOD1 mutation 52
Lack of changes in the PI3K/AKT survival pathway in the spinal cord motor neurons of a mouse model of familial amyotrophic lateral sclerosis. 52
Studies on the enantiomers of RC-33, promising neuroprotective agents acting as sigma1 receptor agonists. Isolation, configurational assignment and biological profile 51
Unraveling the complexity of amyotrophic lateral sclerosis: recent advances from the transgenic mutant SOD1 mice. 50
COMPOSITIONS AND METHODS FOR TARGETING CELLS 50
Chemical, pharmacological and in vivo pharmacokinetic studies on enantiomerically pure RC-33 compounds, promising neuroprotective agents acting as sigma1 receptor agonists 48
Differences in protein quality control correlate with phenotype variability in 2 mouse models of familial amyotrophic lateral sclerosis 48
Heterogeneity of neuroinflammatory responses in amyotrophic lateral sclerosis: A challenge or an opportunity? 42
Sigma1 Receptor Agonists in motor dysfunction pathologies treatment – a medicinal chemistry perspective 41
Neurophysiological characterisation of the g93a ALS rat model 39
COMPOSITIONS AND METHODS FOR TREATING DISEASES AND DISORDERS OF THE CENTRAL NERVOUS SYSTEM 39
Toward the identification of neuroprotective agents: G-scale synthesis, pharmacokinetic evaluation and CNS distribution of (R)-RC-33, a promising SIGMA1 receptor agonist 37
Hydrazone linked doxorubicin-PLA prodrug nanoparticles with high drug loading 35
Intracerebroventricular delivery of hematopoietic progenitors results in rapid and robust engraftment of microglia-like cells 31
Bitopic Sigma 1 Receptor Modulators to Shed Light on Molecular Mechanisms Underpinning Ligand Binding and Receptor Oligomerization 31
Delivery Platforms for CRISPR/Cas9 Genome Editing of Glial Cells in the Central Nervous System 31
Lentiviral vectors carrying enhancer elements of Hb9 promoter drive selective transgene expression in mouse spinal cord motor neurons. 30
Lipophilic dye-compatible brain clearing technique allowing correlative magnetic resonance/high-resolution fluorescence imaging in rat models of glioblastoma 29
Synthesis and characterization of a “clickable” pbr28 tspo-selective ligand derivative suitable for the functionalization of biodegradable polymer nanoparticles 28
T1-weighted dynamic contrast-enhanced MRI is a noninvasive marker of epidermal growth factor receptor VIII status in cancer stem cell-derived experimental glioblastomas 21
Biodegradable polymeric nanoparticles administered in the cerebrospinal fluid: Brain biodistribution, preferential internalization in microglia and implications for cell-selective drug release 21
Fast deep learning reconstruction techniques for preclinical magnetic resonance fingerprinting 18
Metallothioneins are neuroprotective agents in lysosomal storage disorders 18
Simultaneous flow cytometric characterization of multiple cell types retrieved from mouse brain/spinal cord through different homogenization methods 14
Novel S1R agonists counteracting NMDA excitotoxicity and oxidative stress: A step forward in the discovery of neuroprotective agents 11
Discovery of RC-752, a Novel Sigma-1 Receptor Antagonist with Antinociceptive Activity: A Promising Tool for Fighting Neuropathic Pain 11
An innovative hematopoietic stem cell gene therapy approach benefits CLN1 disease in the mouse model 9
null 9
Therapeutic efficacy of intracerebral hematopoietic stem cell gene therapy in an Alzheimer's disease mouse model 4
Totale 1.677
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.987
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.987
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020103 0 0 0 0 3 12 2 15 5 20 31 15
2020/2021164 14 12 4 14 3 18 1 41 17 18 16 6
2021/2022173 7 2 8 3 5 7 7 15 16 6 18 79
2022/2023529 56 54 1 33 43 58 0 29 231 2 12 10
2023/2024230 27 30 7 10 22 59 5 18 2 10 36 4
2024/2025110 20 44 13 18 15 0 0 0 0 0 0 0
Totale 1.677